Evolent Health, Inc. (EVH) stock
EVHNYSEServices-Management ServicesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3029% below fair value
$4.90+0.13 (+2.73%)
Close on Nov 13, 2026Market cap $553.99MP/E –Yield –
Evolent Health r&d expenses
Research and development expenses are spending on new products and technology.
Evolent Health's R&D Expenses for the twelve months ending Sep 30, 2022 was $16.10M. For fiscal 2021 it was $15.50M, up 2.6% from the year before. The highest annual figure on record is $19.80M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $15.50M | +2.6% |
| FY2020 | Dec 31, 2020 | $15.10M | -23.7% |
| FY2019 | Dec 31, 2019 | $19.80M | +8.8% |
| FY2018 | Dec 31, 2018 | $18.20M | +5.8% |
| FY2017 | Dec 31, 2017 | $17.20M | +55.0% |
| FY2016 | Dec 31, 2016 | $11.10M | +91.4% |
| FY2015 | Dec 31, 2015 | $5.80M | – |
| FY2014 | Dec 31, 2014 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $2.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | $3.80M | -9.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.80M | +11.8% |
| Q1 FY2022 | Mar 31, 2022 | $4.10M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.40M | – |
| Q3 FY2021 | Sep 30, 2021 | $4.20M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.40M | – |
See a number that looks wrong?